Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 188 clinical trials
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

. Therefore, investigators generate the hypothesis that adding vascular endothelial growth factor (VEGF) monoclonal antibody, Bevacizumab, to standard neoadjuvant CCRT may improve outcome for patients with

  • 0 views
  • 23 Jan, 2021
  • 1 location
Salvage Therapy With Sunitinib Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

vascular endothelial growth factor (VEGF) receptors. Besides, the expression of the VEGF ligands is also correlated with increased tumor angiogenesis, as well as shortened survival time. One

stage iv non-small cell lung cancer
lung carcinoma
growth factor
serum bilirubin level
solid tumour
  • 2 views
  • 08 Nov, 2020
  • 1 location
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.

esophageal cancer
platelet count
fluorouracil
metastasis
ct scan
  • 11 views
  • 07 Nov, 2020
  • 1 location
Extension Study of MYL-1701P-3001 for Safety and Efficacy

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.

  • 0 views
  • 28 Jan, 2021
  • 1 location
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer

adenocarcinoma
heparin
international normalized ratio
tipiracil
regorafenib
  • 0 views
  • 27 Jan, 2021
  • 21 locations
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

The purpose of this study is to evaluate the efficacy and safety of avastin combined with gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line treatment in patients with untreated natural killer(NK)/T cell lymphoma

  • 9 views
  • 07 Nov, 2020
  • 1 location
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment. Secondary Study Objectives - To monitor adverse events and changes in hemoglobin …

hypogonadism
testosterone
  • 209 views
  • 07 Nov, 2020
  • 2 locations
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1 immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple cancer types, including patients with advanced hepatocellular carcinoma (HCC). The safety profile and optimal dosage of targeted therapy should be carefully evaluated by clinical trials. Regorafenib …

  • 0 views
  • 28 Jan, 2021
  • 1 location
sEphB4-HSA in Treating Patients With Kaposi Sarcoma

This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.

  • 0 views
  • 28 Jan, 2021
  • 8 locations
Doxycycline for Hereditary Hemorrhagic Telangiectasia

This study will investigate the effectiveness of oral doxycycline for the treatment of recurrent nasal hemorrhage in Hereditary Hemorrhagic Telangiectasia (HHT) subjects. The primary outcome for the trials will be the reduction of epistaxis severity (minutes of bleeding per week). The biological outcomes of interest are the regression of vascular …

  • 2 views
  • 25 Jan, 2021
  • 1 location